NMTR Insider Trading Activity and SEC Form 4 Filings
NMTR insider trading summary
No open-market insider purchases or sales of 9 Meters Biopharma, Inc. (NMTR) have been reported on SEC Form 4 in the past 12 months.
Latest NMTR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 21, 2023 | Bethany Sensenig | Chief Financial Officer | Sell | $11K (9,100 @ $1.21) |
| Jul 6, 2022 | John Temperato | Chief Executive Officer | Buy | $28K (125,000 @ $0.23) |
| Jul 1, 2022 | Mark A Sirgo | Director | Buy | $43K (175,000 @ $0.25) |
| May 23, 2022 | Michael T. Constantino | Director | Buy | $8K (16,000 @ $0.48) |
| May 18, 2022 | Mark A Sirgo | Director | Buy | $50K (106,383 @ $0.47) |
| May 18, 2022 | John Temperato | Chief Executive Officer | Buy | $22K (50,000 @ $0.45) |
| Mar 3, 2022 | John Temperato | Chief Executive Officer | Buy | $56K (100,000 @ $0.56) |
| Mar 3, 2022 | Mark A Sirgo | Director | Buy | $50K (86,449.55 @ $0.58) |
| Dec 2, 2021 | Mark A Sirgo | Director | Buy | $45K (50,000 @ $0.89) |
| Nov 18, 2021 | John Temperato | Chief Executive Officer | Buy | $53K (50,000 @ $1.05) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.